Evidence map›Paper›PMID 33256255›Full record

ArticlePharmaceutics2020

Semi-Mechanistic Pharmacokinetic Model to Guide the Dose Selection of Nimotuzumab in Patients with Autosomal Dominant Polycystic Kidney Disease.

Niurys de Castro-Suárez, Mirjam N Trame, Mayra Ramos-Suzarte, José M Dávalos, Raymed A Bacallao-Mendez, Anaelys R Maceo-Sinabele, Víctor Mangas-Sanjuán, Gledys Reynaldo-Fernández, Leyanis Rodríguez-Vera

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 80% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Niurys de Castro-SuárezPharmacy Department, Institute of Food and Pharmacy, University of Havana,Havana 11300, Cuba.
Mirjam N TrameAVROBIO Inc., Department of Translational Data Sciences and Advanced Analytics, Cambridge, MA 02139, USA.
Mayra Ramos-SuzarteCenter of Molecular Immunology (CIM), Havana 11300, Cuba.
José M DávalosNational Institute of Nephrology (INEF), Havana 10400, Cuba.
Raymed A Bacallao-MendezNational Institute of Nephrology (INEF), Havana 10400, Cuba.
Anaelys R Maceo-SinabeleNational Center Coordinating of Clinical Trials (CENCEC), Havana 11300, Cuba.
Víctor Mangas-SanjuánDepartment of Pharmacy and Pharmaceutical Technology and Parasitology, University of Valencia, Valencia 46100, Spain.ORCID 0000-0002-3388-5023
Gledys Reynaldo-FernándezPharmacy Department, Institute of Food and Pharmacy, University of Havana,Havana 11300, Cuba.
Leyanis Rodríguez-VeraPharmacy Department, Institute of Food and Pharmacy, University of Havana,Havana 11300, Cuba.ORCID 0000-0003-1688-7008
University of Havana · CUCenter of Molecular Immunology (Cuba) · CUUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease characterized by an overexpression of epidermal growth factor receptor (EGFR). Nimotuzumab is a recombinant humanized monoclonal antibody against human EGFR. The aim of this study was to develop a population pharmacokinetic model for nimotuzumab and to identify demographic and clinical predictive factors of the pharmacokinetic variability. The population pharmacokinetics (PopPK) of nimotuzumab was characterized using a nonlinear mixed-effect modeling approach with NONMEM

Indexed as

autosomal dominant polycystic kidney diseaseEGFRnimotuzumabNONMEMpopulation analysissemi-mechanistic pharmacokinetics

Identifiers

PMID33256255
PMCPMC7760646
OpenAlexW3107661891

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.